Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
RANDOMIZED TRIAL OF RADIATION-THERAPY (RT) PLUS DIBROMODULCITOL (DBD)VERSUS RT PLUS BCNU IN HIGH-GRADE ASTROCYTOMA
Autore:
ELLIOTT TE; DINAPOLI RP; OFALLON JR; KROOK JE; EARLE JD; MORTON RF; LEVITT R; TSCHETTER LK; SCHEITHAUER BW; PFEIFLE DM; TWITO DI; NELIMARK RA;
Indirizzi:
MAYO CLIN & MAYO FDN,200 1ST ST SW ROCHESTER MN 55905 MAYO CLIN & MAYO FDN ROCHESTER MN 55905 DULUTH COMMUNITY CLIN ONCOL PROGRAM DULUTH MN 55805 IOWA ONCOL RES ASSOC,CCOP DES MOINES IA 50314 CCOP,MERITCARE HOSP FARGO ND 58123 SIOUX COMMUNITY CANC CONSORTIUM SIOUX FALLS SD 57105 QUAIN & RAMSTAD CLIN BISMARCK ND 58506 BILLINGS CLIN BILLINGS MT 59103
Titolo Testata:
Journal of neuro-oncology
fascicolo: 3, volume: 33, anno: 1997,
pagine: 239 - 250
SICI:
0167-594X(1997)33:3<239:RTOR(P>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
ANAPLASTIC GLIOMAS; MALIGNANT GLIOMA; RADIOTHERAPY; CHEMOTHERAPY; PROCARBAZINE; SURGERY; CCNU;
Keywords:
HIGH GRADE ASTROCYTOMA; DIBROMODULCITOL; BCNU; RADIATION THERAPY; CHEMOTHERAPY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
27
Recensione:
Indirizzi per estratti:
Citazione:
T.E. Elliott et al., "RANDOMIZED TRIAL OF RADIATION-THERAPY (RT) PLUS DIBROMODULCITOL (DBD)VERSUS RT PLUS BCNU IN HIGH-GRADE ASTROCYTOMA", Journal of neuro-oncology, 33(3), 1997, pp. 239-250

Abstract

Purpose: We performed a randomized trial to compare survival distributions and toxicity of radiation therapy (RT) and DBD with RT and BCNU in patients with high-grade astrocytoma. Methods: A total of 238 patients with supratentorial grade 3 and grade 4 astrocytoma were studied. Patients were stratified by age, extent of surgery, tumor grade, and performance score and randomly assigned to receive RT 55-60 Gy and either DBD, 200 mg/m(2) orally on Days 1-10 every five weeks or BCNU, 200 mg/m(2) intravenously every seven weeks. Median age was 60 years; 62% were 55 years or older. Eighty-three percent had subtotal resection, 58% had grade 4 tumors, and 83% had performance scores of 0-2. Results:Survival distributions for all patients in the two arms were similar,with median survival of 41 weeks in each arm. Time to progression distributions were virtually identical, with medians of 22 weeks. BCNU produced significantly greater hematologic toxicity; median leukocyte and platelet nadirs on the first cycle were 3.6 vs. 4.7 (P = 0.0001) and117 vs. 162 (P < 0.0001), and overall platelet nadirs were 80.5 vs. 114 (P = 0.0019). Non-hematologic toxicities were also significantly greater with BCNU, including nausea (57% vs. 31%; P < 0.0001) and vomiting (45% vs. 17%; P < 0.0001). Conclusion: This trial found no evidenceof differences in treatment efficacy when either DBD or BCNU is combined with radiation therapy for patients with high-grade astrocytoma.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 09:13:10